IP Library Granted Patent US 10,047,151
Granted Patent B2
US 10,047,151 · App. 15/150,227 · Granted Aug 14, 2018

Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Inventors: Antonia Lopez-Girona (San Diego, CA); Peter H. Schafer (Belle Mead, NJ); Anita Gandhi (Bernardsville, NJ); Derek Mendy (San Diego, CA); Thomas O. Daniel (La Jolla, CA)
Assignee: CELGENE CORPORATION
C07K16/18C12Q1/6886G01N33/5743G01N33/57426G01N33/57484C07K2317/34C07K2317/51C07K2317/515C12Q2600/106C12Q2600/156C12Q2600/158G01N21/6428G01N2333/47G01N2800/52G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,151
App. No.
15/150,227
Granted
Aug 14, 2018
Kind
B2
Abstract

Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

Claims (7)

1. An isolated antibody or antigen binding fragment thereof that immunospecifically binds to an epitope in CRBN, wherein the epitope has the amino acid sequence SEQ ID NO:1, and wherein the isolated antibody comprises

(i) a heavy chain having complementarity determining regions (CDRs) consisting of the amino acids of the CDRs of SEQ ID NO: 5 and a light chain having complementarity determining regions (CDRs) consisting of the amino acids of the CDRs of SEQ ID NO: 7; or

(ii) a heavy chain having complementarity determining regions (CDRs) consisting of the amino acids of the CDRs of SEQ ID NO: 9 and a light chain having complementarity determining regions (CDRs) consisting of the amino acids of the CDRs of SEQ ID NO: 11.

2. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the isolated antibody comprises a heavy chain having the amino acid sequence depicted in SEQ ID NO:5 and a light chain having the amino acid sequence depicted in SEQ ID NO:7.

3. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the isolated antibody comprises a heavy chain having the amino acid sequence depicted in SEQ ID NO:9 and a light chain having the amino acid sequence depicted in SEQ ID NO:11.

4. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the isolated antibody comprises a heavy chain variable region consisting of the amino acids of the heavy chain variable region of SEQ ID NO: 5 and a light chain variable region consisting of the amino acids of the light chain variable region of SEQ ID NO: 7.

5. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the isolated antibody comprises a heavy chain variable region consisting of the amino acids of the heavy chain variable region of SEQ ID NO: 9 and a light chain variable region consisting of the amino acids of the light chain variable region of SEQ ID NO: 11.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: LOPEZ-GIRONA, ANTONIA; SCHAFER, PETER H.; GANDHI, ANITA; MENDY, DEREK
To: CELGENE CORPORATION
Reel/Frame 040155/0336 →
Continuity (5)
Continuation 13459005 · Apr 27, 2012
Provisional Application 61579600 · Dec 22, 2011
Provisional Application 61511986 · Jul 26, 2011
Provisional Application 61481066 · Apr 29, 2011
Related Publication 20160319005A1 · Nov 3, 2016
Cited By (5)
US 12,208,095 US 12,312,316 US 12,461,103 US 12,474,342 US 12,496,301